Questions that our clients ask
- How will non-cell and gene therapies competing within a given disease space impact payer and provider perceptions of a cell / gene therapy’s value?
- How can we best differentiate our value proposition and corresponding launch strategy?
- What evidence should be developed to support the unique value proposition of cell and gene therapies, given some of the inherent limitations such as single-arm trial, short follow-up?
- How can alternative payment models be leveraged to gain access and optimize pricing?
- How will the unique one-time administration feature, paired with a significant upfront price point, impact access and utilization?
- How can we navigate the reimbursement implications of inpatient cell or gene therapy administration (particularly for Medicare and Medicaid patients) to minimize provider-level financial exposure and ensure hospitals receive sufficient payment for treatment?
Specialist therapeutic areas
Oncology cell therapies and rare disease gene therapies.
Specialized markets
The CBP difference
- We help clients to navigate this rapidly evolving landscape
- We think outside the box and customize strategies while being a partner throughout the process
- We use targeted recruitment to ensure we reach the right stakeholders